Elequin Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Elequin Capital’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12	Closed	–	–	726
2022 Q2	$0	Buy	12 +3	+33%	+$4	﹤0.01%	459
2022 Q1	$0	Buy	+9	New	+$18	﹤0.01%	351

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Elequin Capital's CLVS Position: Q3 2022 in Review

Elequin Capital sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 12 shares.

Elequin Capital first reported a position in CLVS in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

Elequin Capital reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
Elequin Capital sold 12 Clovis Oncology, Inc. shares in Q3 2022.
Elequin Capital first reported a position in Clovis Oncology, Inc. in Q1 2022 and held it in 2 quarters.
Elequin Capital's Clovis Oncology, Inc. position peaked at $0 in Q2 2022.
103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Elequin Capital's 13F filing for Q3 2022, filed 10 Nov 2022.